Treatment ‘mismatch’ in early prostate cancer

Pretreatment urinary, bowel, and sexual dysfunction may increase the toxicity of prostate cancer treatments or preclude potential benefits. Using patient‐reported baseline dysfunction from a prospective cohort study, we determined the proportion of patients receiving relatively contraindicated (‘mismatched’) treatments.

[1]  S. P. Mitchell,et al.  Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. , 2006, The Journal of urology.

[2]  F. Montorsi,et al.  Baseline potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. , 2006, European urology.

[3]  J. Steiner,et al.  Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote , 2006, Cancer.

[4]  L. Kaçi,et al.  Letters to the Editor/ErrataRE: THE IMPACT OF OPEN RADICAL RETROPUBIC PROSTATECTOMY ON CONTINENCE AND LOWER URINARY TRACT SYMPTOMS: A PROSPECTIVE ASSESSMENT USING VALIDATED SELF-ADMINISTERED OUTCOME INSTRUMENTS , 2005 .

[5]  A. Henderson,et al.  Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  Galina Velikova,et al.  Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Ronald C. Chen,et al.  Time course and predictors of symptoms after primary prostate cancer therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Aaronson,et al.  Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. , 2002, JAMA.

[9]  Jack Clark,et al.  Symptom Indexes to Assess Outcomes of Treatment for Early Prostate Cancer , 2001, Medical care.

[10]  M. Litwin,et al.  Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. , 2000, The Journal of urology.

[11]  R A Stephenson,et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. , 2000, Journal of the National Cancer Institute.

[12]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[13]  D. Lubeck,et al.  Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. , 1999, Urology.

[14]  W. Catalona,et al.  Contemporary results of anatomic radical prostatectomy , 1999, CA: a cancer journal for clinicians.

[15]  I. Osterloh,et al.  Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. , 1999, Urology.

[16]  M. Barry,et al.  Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Barry,et al.  Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. , 1995, Urology.

[18]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[19]  M. Barry,et al.  Patient-re ported complications and follow-up treatment after radical prostatectomy , 1993 .

[20]  P. Walsh,et al.  Impact of anatomical radical prostatectomy on urinary continence. , 1991, The Journal of urology.

[21]  W. Catalona,et al.  Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. , 1990, The Journal of urology.

[22]  P. O'Donnell,et al.  Continence following nerve-sparing radical prostatectomy. , 1989, The Journal of urology.

[23]  R. Elashoff,et al.  Flaws in mortality data. The hazards of ignoring comorbid disease. , 1988, JAMA.

[24]  P. Walsh.  Predictive factors of urinary retention following prostate brachytherapy. , 2003, The Journal of urology.

[25]  P. Walsh.  Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. , 2000, The Journal of urology.

[26]  P. Walsh,et al.  Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. , 1998, The Journal of urology.

[27]  F. Marshall,et al.  Risk factors for urinary incontinence after radical prostatectomy. , 1996, The Journal of urology.

[28]  M. Barry,et al.  Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). , 1993, Urology.